Business Wire

CA-ARMIS

12.12.2023 14:01:40 CET | Business Wire | Press release

Share
Armis Named Leader in Three Q4 2023 Quadrant SPARK Matrix™ Reports

Armis, the asset intelligence cybersecurity company, today announced that it has been named a leader by analyst group Quadrant Knowledge Solutions in three 2023 SPARK Matrix™ reports for Q4 2023. The reports: SPARK Matrix™: Vulnerability Management, Q4 2023, SPARK Matrix™: Operational Technology (OT) Security, Q4 2023, and SPARK Matrix™: Connected Medical Device Security Solutions, Q4 2023, place three Armis Centrix™ solutions as a Technology Leader with significant customer impact in the areas of Vulnerability Management, Operational Technology Security and Connected Medical Device Security.

“Our Leader position in these three reports is a testament to our commitment to innovation and customer success, and helping organizations see, protect and manage their entire attack surface in real-time,” said Dana Gilboa, Chief Product Officer of Armis. “We are extremely proud that Armis is positioned as a Leader on both the Technology Leader axis and the Customer Impact axis for all three reports. We also want to extend a sincere thank you to the Armis customers who took the time to provide feedback on Armis to Quadrant Knowledge Solutions.”

The SPARK Matrix™ reports analyzed three of Armis’ four core solutions: Vulnerability Management, OT/IoT Security, and Medical Device Security, which are all built on Armis Centrix™, the Armis cyber exposure management platform. Powered by the Armis AI-driven Asset Intelligence Engine, Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively identifies all cyber asset risks, remediates vulnerabilities, blocks threats and protects the entire attack surface.

SPARK Matrix™ reports analyze the vendor landscape of a technology category and vendor product capabilities. Vendors are evaluated according to their product offerings, market share and customer satisfaction to help CIOs and CISOs make informed technology decisions.

When evaluating why Armis is a technology leader in each of these three core areas, Quadrant Knowledge Solutions shared in its reports:

  • Vulnerability Management - “Armis Centrix™ for Vulnerability Prioritization and Remediation bridges critical coverage gaps unattended by Vulnerability assessment tools with aggregation of details such as ownership and location to create full visibility of the attack surface. Armis Centrix™ for Vulnerability Prioritization and Remediation provides holistic visibility into the user’s overall risk and attack surface. The platform also provides the business context of business-critical assets based on their roles. Armis Centrix™ Asset Vulnerability Prioritization and Remediation helps the organization reduce its attack surface by analyzing attributes of devices and overlaying threat intel as a part of the analysis.”
  • Operational Technology Security - “Armis Centrix™ for OT/IoT security enables organizations to see and secure OT/IOT networks and physical assets, ensure uptime, and build an effective & comprehensive security strategy. It is powered by Armis’ AI-driven Asset Intelligence Engine and oversees, secures, protects, and manages a wide range of assets in real-time. The cloud-based platform proactively mitigates all cyber asset risks, remediates vulnerabilities, blocks threats, and protects the entire attack surface. Armis for OT/IoT security provides deep visibility to all OT assets as well as to the OT/ICS networks and environment. It allows companies to manage the OT/IT convergence, bridge the IT / OT gap and protect OT networks, monitor connectivity, and track behavior.”
  • Connected Medical Device Security - “Armis Centrix™ for Medical Device Security offers features like real-time complete visibility into medical device inventory, information regarding device usage for increasing utilization efficiency, medical device risk assessment based on vulnerabilities, identifying Protected Health Information (PHI) breaches, identifying and remediating threats, and automating security of medical devices. The product is also equipped with an Asset Intelligence Engine with over 20 million device profiles, and the AI-powered Armis Standard Query.”

Learn more about each of these Quadrant Knowledge Solutions reports at the below links:

To read our blog, please visit: https://www.armis.com/blog/armis-is-named-a-leader-in-three-2023-quadrant-spark-matrix-reports/

For additional analyst reports sharing insights about Armis Centrix™, go here: https://www.armis.com/resources/?type=analyst-reports

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231212672034/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release

Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release

Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto

ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release

Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ

NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release

The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term

Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye